Amendments to the Claims:

1. **(Currently Amended):** A N-radiohaloaryl-alkylcarboxamide radioligand wherein the alkyl moiety thereof is ~~provided by a branched hydrophobic carbon unit, the carbon unit formed by acyclic alkyl groups and/or cycloalkanes~~ a cyclohexane radical, the radioligand having a high affinity to TRP-M8 receptors in cells and tissues and having a specific activity of at least about 20 Ci/mmol or greater, wherein the TRP-M8 affinity is characterized by a Kd of about 1×10^{-5} or less.

2. **(Previously Presented):** The radioligand as in claim 1 wherein the radiohalo moiety is covalently bound in the molecule.

3. **(Previously Presented):** The radioligand as in claim 2 wherein the radiohalo moiety is selected from fluoride and iodide radionuclides.

4. **(Previously Presented):** The radioligand as in claim 3 wherein the specific activity is about 250 Ci/mmol or greater.

5. **(Currently Amended):** The radioligand as in claim 1 wherein the ~~alkyl moiety is represented by R-, and wherein R is a saturated or monoethylenically unsaturated alkyl-substituted cyclic or bicyclic alkyl radical containing a total of 7-14 carbon atoms and is selected from the group cyclopentanes, cyclohexanes, cycloheptanes, cyclooctanes, cyclononanes, [3.1.1]bicycloheptanes and hept-5-enes, [2.2.1]bicyclo-heptanes and hept-5-enes, and [2.2.2]bicyclooctanes and oct-5-enes, the alkyl radical containing~~ cyclohexane radical contains from 1 to 3 $C_1 - C_5$ normal or branched alkyl substituents.

6. **Cancelled.**

7. **(Previously Presented):** The radioligand as in claim 1 wherein the aryl moiety is a substituted aromatic radical represented by Y-, the substituents being

represented by $\mathbf{R_1}$, $\mathbf{R_2}$, and **X**, wherein

$\mathbf{R_1}$ is selected from the group hydrogen, hydroxyl, $C_1 - C_3$ alkoxy, $C_1 - C_3$ carboxyalkyl, $C_1 - C_3$ oxycarbonylalkyl,

$\mathbf{R_2}$ is selected from the group hydrogen, hydroxyl, $C_1 - C_3$ alkoxy, trifluoromethyl, nitro, cyano, halo, and

X is selected from the group $[^{18}F]$-, $[^{123}I]$-, $[^{125}I]$-, and $[^{131}I]$-.

8. **(Previously Presented):** The radioligand as in claim 7 wherein the aromatic radical includes monoaromatic rings, polyaromatic rings or heterocyclic aromatic rings.

9. **(Previously Presented):** Use of the radioligand of claim 1 in radioreceptor assays.

10. **(Previously Presented)** Use of the radioligand of claim 1 for scanning or imaging tissues bearing the TRP-M8 receptor.

11. **(Currently Amended):** A composition comprising a N-radiohaloaryl-alkylcarboxamide of Formula 1:

Formula 1

R-CONH-Y

where (a) **R** is a ~~saturated or monoethylenically unsaturated alkyl substituted cyclic or bicyclic alkyl radical containing a total of 7-14 carbon atoms selected from the group cyclopentanes, cyclohexanes, cycloheptanes, cyclooctanes, cyclononanes, [3.1.1]bicyclo-heptanes and hept-5-enes, [2.2.1]bicyclo-heptanes and hept-5-enes, and [2.2.2]bicyclo-octanes and oct-5-enes, the alkyl radical~~ cyclohexane radical containing from 1 to 3 C_1 –

C_5 normal or branched alkyl substituents, and (b) **Y** is a substituted aromatic radical containing substituents $\mathbf{R_1}$, $\mathbf{R_2}$, and **X**, wherein

$\mathbf{R_1}$ is selected from the group hydrogen, hydroxyl, $C_1 - C_3$ alkoxy, $C_1 - C_3$ carboxyalkyl, $C_1 - C_3$ oxycarbonylalkyl,

$\mathbf{R_2}$ is selected from the group hydrogen, hydroxyl, $C_1 - C_3$ alkoxy, trifluoromethyl, nitro, cyano, halo, and

X is selected from the group [^{18}F]-, [^{123}I]-, [^{125}I]-, and [^{131}I]-.

12. **(Currently Amended):** The composition as in claim 11 wherein the ~~alkyl~~ cyclohexane radical of (a) contains 8-12 carbon atoms and the total number of carbon atoms in the alkyl substituents ~~on the α- and β- ring~~ carbons are from 1 to 5.

13. **(Previously Presented):** The composition as in claim 12 wherein the carboxamide group is in an equatorial position relative to the plane of the ~~cycloalkyl~~ cyclohexyl ring.

14. **(Previously Presented):** The composition as in claim 11 wherein the Formula 1 compound has a specific activity of about 20 Ci/mmol or greater.

15. **(Previously Presented):** The composition as in claim 11 wherein the Formula 1 compound is a ligand for the TRP-M8 receptor.

16. **(Previously Presented):** The composition as in claim 15 wherein the Formula 1 compound has a high affinity for the TRP-M8 receptor.

17. – 22. (Withdrawn).

23. **(Currently Amended):** A method for using a radioactive ligand, comprising:

providing a N-radiohaloaryl-alkylcarboxamide radioligand wherein the alkyl moiety thereof ~~includes acyclic alkyl groups and/or cycloalkanes~~ is a cyclohexane radical, the radioligand

having a ~~determinably~~ high affinity to the TRP-M8 receptor in cells and tissues characterized by a Kd of about 1×10^{-5} or less and having a specific activity of at least about 20 Ci/mmol or greater; and,

contacting the radioligand with cells or tissues under conditions sufficient to permit specific binding between the radioligand and TRP-M8 receptors if said receptors are carried by the cells or tissues.

24. **Cancelled.**

25. **(Previously Presented):** The method as in claim 23 further comprising:

determining the amount or presence of TRP-M8 receptors in the cells or tissues of the contacting.

26. **(Currently Amended):** A *N*-radiohaloaryl-alkylcarboxamide radioligand wherein the alkyl moiety thereof ~~includes~~ comprises a cyclohexane radical and wherein the radiohalo moiety is covalently bound in the molecule , the radioligand having a high affinity to TRP-M8 receptors and having a specific activity of at least about 20 Ci/mmol or greater, wherein the TRP-M8 affinity is characterized by a Kd of about 1×10^{-5} or less.

27. **Cancelled.**

28. **(Currently Amended):** The radioligand as in claim ~~27~~ 26 wherein the radiohalo moiety is selected from fluoride and iodide radionuclides.

29. **Cancelled.**

30. **(Currently Amended):** The radioligand as in claim 26 wherein the ~~alkyl moiety is represented by R', and wherein R' includes~~ cyclohexane radical has from 1 to 3 $C_1 - C_5$ normal or branched alkyl substituents.